Yüklüyor......
Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients
New potent immunomodulatory therapies for multiple sclerosis (MS) are associated with increased risk for progressive multifocal leukoencephalopathy (PML). It is unclear why a subset of treated patients develops PML, but patient age has emerged as an important risk factor. PML is caused by the JC vir...
Kaydedildi:
| Yayımlandı: | Mult Scler |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6013383/ https://ncbi.nlm.nih.gov/pubmed/29774781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458518775550 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|